NVIDIA's BioNeMo platform is being deployed by US pharmaceutical giant Eli Lilly, lab equipment manufacturer Thermo Fisher Scientific, and AI biotech companies including Natera, Basecamp Research, Owkin, Edison Scientific, and Boltz Lab for drug discovery applications.1
The platform delivers pre-trained AI models and tools for molecular biology, protein structure prediction, and drug candidate screening. Researchers can train custom models on proprietary datasets while using NVIDIA's GPU infrastructure optimized for biological data processing.1
Thermo Fisher's integration is significant given its global supply role to research institutions worldwide. The adoption suggests AI model development is becoming standard infrastructure alongside traditional laboratory equipment across international markets.
The biotech firms represent diverse applications spanning genetic testing (Natera), protein discovery from biodiversity data (Basecamp Research), federated learning for medical research (Owkin), materials science (Edison Scientific), and protein structure prediction (Boltz Lab). France-based Owkin's participation highlights European engagement in the platform.
The coordinated adoption across large pharma, equipment manufacturers, and specialized AI biotechs indicates industry-wide standardization rather than isolated internal tool development. Foundation models trained on biological data can identify drug candidates and analyze genetic sequences faster than traditional methods used in research centers from Boston to Basel.
NVIDIA's strategy positions its GPU infrastructure as essential for global biotechnology research, mirroring its dominance in AI sectors worldwide. The company provides both computational hardware and domain-specific software frameworks, creating an integrated ecosystem for life sciences research.
The deployment scale suggests drug discovery workflows are being redesigned around AI capabilities globally. Companies are building new research pipelines with AI models as the primary analytical engine rather than using AI to augment existing processes.
